These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Cancer; 2005 Oct 15; 104(8):1661-7. PubMed ID: 16149091 [Abstract] [Full Text] [Related]
17. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry. Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU. Transplantation; 2012 Mar 15; 93(5):543-50. PubMed ID: 22234349 [Abstract] [Full Text] [Related]
18. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, Fernberg P, Sundström C, Pauksens K, Enblad G. Acta Oncol; 2014 May 15; 53(5):669-79. PubMed ID: 24164103 [Abstract] [Full Text] [Related]